Driehaus Capital Management LLC Has $33.86 Million Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Driehaus Capital Management LLC increased its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 17.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,028,667 shares of the biotechnology company’s stock after purchasing an additional 447,743 shares during the period. Driehaus Capital Management LLC’s holdings in ADMA Biologics were worth $33,860,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ADMA. LSV Asset Management bought a new stake in shares of ADMA Biologics during the 1st quarter worth about $1,028,000. Seven Eight Capital LP acquired a new position in ADMA Biologics during the second quarter valued at approximately $1,992,000. BNP Paribas Financial Markets lifted its stake in shares of ADMA Biologics by 152.2% in the first quarter. BNP Paribas Financial Markets now owns 732,920 shares of the biotechnology company’s stock worth $4,837,000 after buying an additional 442,315 shares during the last quarter. Alberta Investment Management Corp lifted its stake in shares of ADMA Biologics by 32.4% in the fourth quarter. Alberta Investment Management Corp now owns 460,774 shares of the biotechnology company’s stock worth $2,083,000 after buying an additional 112,831 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in shares of ADMA Biologics by 90.7% during the 1st quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock worth $7,717,000 after buying an additional 556,175 shares during the period. 75.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ADMA. HC Wainwright lifted their target price on shares of ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Mizuho lifted their price objective on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, June 20th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $15.50.

Insider Transactions at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the transaction, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $16.90, for a total value of $408,135.00. Following the completion of the transaction, the chief operating officer now directly owns 449,088 shares of the company’s stock, valued at approximately $7,589,587.20. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the transaction, the director now owns 153,941 shares of the company’s stock, valued at $2,843,290.27. The disclosure for this sale can be found here. In the last quarter, insiders have sold 466,900 shares of company stock valued at $8,224,121. 3.70% of the stock is owned by corporate insiders.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $19.39 on Friday. The company’s fifty day moving average is $16.27 and its two-hundred day moving average is $11.30. ADMA Biologics, Inc. has a 52-week low of $3.06 and a 52-week high of $20.16. The company has a debt-to-equity ratio of 0.74, a current ratio of 6.87 and a quick ratio of 2.80. The firm has a market capitalization of $4.49 billion, a price-to-earnings ratio of -969.25 and a beta of 0.61.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The business had revenue of $107.20 million for the quarter, compared to the consensus estimate of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The firm’s revenue for the quarter was up 78.4% compared to the same quarter last year. During the same period last year, the business earned ($0.02) earnings per share. Equities research analysts forecast that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.